Claim Ledger
67% answered
Did management answer the analysts?
12 analyst questions audited, 2 evaded or deflected.
View Claim Ledger →
Aarti Industries Ltd — Q4 FY26
Aarti Industries reported Q4 FY26 revenue of ₹2,422 crore (+9% YoY) and EBITDA of ₹342 crore (+29% YoY), with PAT surging 43% YoY to ₹137 crore.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Aarti Industries reported Q4 FY26 revenue of ₹2,422 crore (+9% YoY) and EBITDA of ₹342 crore (+29% YoY), with PAT surging 43% YoY to ₹137 crore. The quarter was marked by severe raw material inflation (benzene, sulfur up >60%) and Middle East geopolitical disruptions, which impacted ~10% of revenue from energy exports. Management highlighted two new long-term contracts: a backward integration deal with a global chemical major (₹200-250 crore capex, 15-year tenure) and a $150 million multi-year agrochemical intermediate supply agreement. Capacity utilization remains high (>80%), and Zone 4 projects (MTP, PA, calcium chloride) are commissioning with a 3-4 month delay due to labor shortages. FY27 capex guidance is ₹700-800 crore, down from ₹1,125 crore. Near-term risks include sustained West Asia conflict disrupting feedstock and export flows, and elevated working capital due to higher raw material prices and longer transit times.
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Prolonged Middle East conflict disrupting exports and raw material supply
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Export share of revenue
57%
+? pp YoY
Exports contributed 57% of total revenue in Q4, up from prior periods, driven by rerouting volumes from Middle East to other regions.
Middle East revenue exposure
9-10%
flat YoY
Approximately 9-10% of annual revenue comes from Middle East, predominantly in energy applications, now disrupted by geopolitical tensions.
Capacity utilization (energy chain)
>80%
+? pp YoY
Capacity utilization in energy applications remained high despite a 4% QoQ volume decline due to Middle East disruptions.
Net debt to EBITDA
3.6x
+?x YoY
Net debt/EBITDA stood at 3.6x as of March 31, 2026, up from prior year due to elevated working capital and capex.
What Changed vs Last Quarter
NEW
FY27 capex guidance of ₹700-800 crore
Management guided FY27 capex in the range of ₹700-800 crore, down from ₹1,125 crore in FY26, focusing on completion of Zone 4 and new contract capex.
NEW
Zone 4 commissioning during FY27
All Zone 4 assets (MTP, PA, calcium chloride, five chemistry blocks) will be commissioned during FY27, with initial revenue from Q2 FY27.
NEW
Net debt to decline in FY27
Management expects net debt to decline in FY27 as capex intensity reduces and operating cash flows improve, despite working capital pressures.
NEW
Effective tax rate of 9-15% in FY27
Tax rate expected in the range of 9-15% for FY27, benefiting from depreciation on Zone 4 assets and resolution of prior litigations.
DROPPED
MMA capacity expansion to 360 KT by Q4 FY26
Debottlenecking from 290+ KT to 360 KT, expected to be completed by end of Q4 FY26.
DROPPED
Zone 4 commissioning in calendar year 2026
Calcium chloride and multi-purpose plant to be commissioned in Q4 FY26; remaining process blocks through CY26.
DROPPED
FY27 capex significantly lower than FY26
FY26 capex guided at ₹1,100 crore; FY27 expected to be much lower as Zone 4 capex largely completes.
DROPPED
Mid-term EBITDA target by FY28
Management reiterated commitment to mid-term EBITDA target (previously communicated) by FY28.
NEW RISK
Prolonged Middle East conflict disrupting exports and raw material supply
The West Asia war has shut ~10% of revenue from Middle East energy exports and caused >60% spike in key raw material prices, with full Q1 impact yet to be felt.
NEW RISK
Elevated working capital and debt levels
Net debt rose to ₹4,300 crore (3.6x EBITDA) due to higher raw material prices and longer export transit times; normalization may take time.
NEW RISK
Margin pressure in agrochemical segment from Chinese competition
Despite some recovery in select chains, agrochemical margins remain under pressure from Chinese oversupply; broad-based recovery uncertain.
NEW RISK
Delay in Zone 4 commissioning impacting EBITDA target timeline
Zone 4 projects delayed by 3-4 months due to labor shortages, potentially pushing back the targeted ₹300-450 crore EBITDA contribution from these assets.
RISK GONE
Sustained pricing pressure in agrochemicals and pharma
Pricing remains subdued due to persistent dumping from China; recovery depends on China's anti-involution actions.
RISK GONE
Zone 4 ramp-up delays
Specialty products require customer qualification cycles; meaningful utilization may take up to 2 years.
RISK GONE
US tariff impact on PDA chain
PDA product chain faced volume and pricing pressure due to large US dependency; recovery hinges on trade deal details.
RISK GONE
Potential negative impact from EU imports into India
Analyst raised risk of European competitors importing into India under FTA; management downplayed but acknowledged possibility.
Fast read
Guidance and risk preview
Management guided FY27 capex in the range of ₹700-800 crore, down from ₹1,125 crore in FY26, focusing on completion of Zone 4 and new contract capex.
The West Asia war has shut ~10% of revenue from Middle East energy exports and caused >60% spike in key raw material prices, with full Q1 impact ye...
View Risks →